CHICAGO (EGMN) - Vandetanib, a multitargeted experimental agent, significantly delayed progression of locally advanced or metastatic medullary thyroid cancer in a randomized, placebo-controlled, phase III trial.At a median of 2 years' follow-up, median progression-free survival had not been reached in 231 patients who were treated with vandetanib (Zactima), but was 19.3 months in 100 patients on placebo. Only 32% of the vandetanib arm had disease progression vs. 51% of the control group (hazard ratio,...